Publications by authors named "Francesca Rocchetti"

Claim this Profile
D
Discovery of BI-2493, a Pan-KRAS Inhibitor Showing Efficacy.
Joachim Bröker, Alex G Waterson, Timothy R Hodges, Jason R Abbott, Allison Arnold, Francesca Rocchetti

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification.
Antonio Tedeschi, Fiorella Schischlik, Francesca Rocchetti, Johannes Popow, Florian Ebner

Mol Cancer Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Donia M Moujalled, Giovanna Pomilio, Corina Ghiurau, Adam Ivey, Jessica Salmon, Francesca Rocchetti

Leukemia· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.
Patrick Casara, James Davidson, Audrey Claperon, Gaëtane Le Toumelin-Braizat, Meike Vogler, Francesca Rocchetti

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia.
Amélie Trinquand, Nuno R Dos Santos, Christine Tran Quang, Francesca Rocchetti, Benedetta Zaniboni

Cancer Discov· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis